Medication used to treat insomnia
Daridorexant Trade names Quviviq Other names Nemorexant; ACT-541468, Daridorexant hydrochloride (USAN US ) License data
Routes of administration By mouth [ 1] Drug class Dual orexin receptor antagonist ; Hypnotic ; Sedative ATC code Legal status
Bioavailability 62%[ 1] Protein binding 99.7%[ 1] Metabolism Extensive (mainly CYP3A4 (89%))[ 1] Onset of action Tmax : 1–2 hours (delayed by 1.3 hours with food)[ 1] Elimination half-life 8 hours (6–10 hours)[ 1] [ 5] Duration of action ~8 hours (50 mg)[ 5] Excretion Feces : ~57%[ 1] Urine : ~28%[ 1]
[(2S )-2-(5-Chloro-4-methyl-1H -benzimidazol-2-yl)-2-methylpyrrolidin-1-yl]-[5-methoxy-2-(triazol-2-yl)phenyl]methanone
CAS Number PubChem CID IUPHAR/BPS DrugBank ChemSpider UNII KEGG ChEMBL PDB ligand CompTox Dashboard (EPA ) ECHA InfoCard 100.353.123 Formula C 23 H 23 Cl N 6 O 2 Molar mass 450.93 g·mol−1 3D model (JSmol )
CC1=C(C=CC2=C1N=C(N2)[C@@]3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl
InChI=1S/C23H23ClN6O2/c1-14-17(24)6-7-18-20(14)28-22(27-18)23(2)9-4-12-29(23)21(31)16-13-15(32-3)5-8-19(16)30-25-10-11-26-30/h5-8,10-11,13H,4,9,12H2,1-3H3,(H,27,28)/t23-/m0/s1
Key:NBGABHGMJVIVBW-QHCPKHFHSA-N
Daridorexant , sold under the brand name Quviviq , is an orexin antagonist medication which is used for the treatment of insomnia .[ 1] [ 4] [ 6] [ 7] [ 8] Daridorexant is taken by mouth .[ 1] [ 4] [ 7]
Side effects of daridorexant include headache , somnolence , and fatigue .[ 1] [ 7] The medication is a dual orexin receptor antagonist (DORA).[ 9] [ 7] [ 10] [ 8] It acts as a selective dual antagonist of the orexin receptors OX1 and OX2 .[ 9] [ 10] [ 8] Daridorexant has a relatively short elimination half-life of 8 hours and a time to peak of about 1 to 2 hours.[ 1] [ 7] [ 5] It is not a benzodiazepine or Z-drug and does not interact with GABA receptors , instead having a distinct mechanism of action .[ 8] [ 7]
Daridorexant was approved for medical use in the United States in January 2022[ 1] [ 11] and became available in May 2022.[ 12] It was approved in the European Union in April 2022, and is the first orexin receptor antagonist to become available in European Union.[ 13] The medication is a schedule IV controlled substance in the United States and may have a modest potential for misuse .[ 1] [ 14] [ 15] Besides daridorexant, other orexin receptor antagonists, like suvorexant and lemborexant , have also been introduced.[ 16] [ 17]
^ a b c d e f g h i j k l m n o "Quviviq- daridorexant tablet, film coated" . DailyMed . 23 March 2022. Archived from the original on 19 September 2022. Retrieved 18 September 2022 .
^ "Summary Basis of Decision for Quviviq" . Health Canada . 4 August 2023. Retrieved 4 October 2023 .
^ "Details for: Quviviq" . Health Canada . 8 September 2023. Retrieved 4 October 2023 .
^ a b c Cite error: The named reference Quviviq EPAR
was invoked but never defined (see the help page ).
^ a b c Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opinion on Drug Metabolism & Toxicology . 16 (11): 1063–1078. doi :10.1080/17425255.2020.1817380 . PMID 32901578 . S2CID 221572078 .
^ "Quviviq Product Information" (PDF) . European Medicines Agency . 2022. Archived (PDF) from the original on 6 May 2022. Retrieved 5 May 2022 .
^ a b c d e f Park J, Render PharmD KP, Cates PharmD DW (January 2023). "Daridorexant: Comprehensive Review of A New Oral Agent for the Treatment of Insomnia". The Annals of Pharmacotherapy . 57 (9): 1076–1087. doi :10.1177/10600280221143794 . PMID 36602018 . S2CID 255473890 .
^ a b c d Roch C, Bergamini G, Steiner MA, Clozel M (October 2021). "Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia" . Psychopharmacology . 238 (10): 2693–2708. doi :10.1007/s00213-021-05954-0 . PMC 8455402 . PMID 34415378 .
^ a b "Daridorexant - Idorsia Pharmaceuticals - AdisInsight" . Archived from the original on 19 June 2018. Retrieved 19 June 2018 .
^ a b Equihua-Benítez AC, Guzmán-Vásquez K, Drucker-Colín R (July 2017). "Understanding sleep-wake mechanisms and drug discovery". Expert Opinion on Drug Discovery . 12 (7): 643–657. doi :10.1080/17460441.2017.1329818 . PMID 28511597 . S2CID 3513546 .
^ "Drug Approval Package: Quviviq" . U.S. Food and Drug Administration (FDA) . 14 February 2022. Archived from the original on 4 March 2022. Retrieved 4 March 2022 .
^ "Idorsia's new treatment QUVIVIQ (Daridorexant) is now available in the US for adults living with insomnia" (Press release). 2 May 2022. Archived from the original on 5 May 2022. Retrieved 5 May 2022 .
^ "Europe's first dual orexin receptor antagonist – Quviviq (Daridorexant) – granted approval to improve both nighttime symptoms and daytime functioning in adults with chronic insomnia disorder" . 3 May 2022. Archived from the original on 5 May 2022. Retrieved 5 May 2022 .
^ Cite error: The named reference Idorsia PR
was invoked but never defined (see the help page ).
^ "Schedules of Controlled Substances: Placement of Daridorexant in Schedule IV" . Archived from the original on 13 April 2022. Retrieved 13 April 2022 . This article incorporates text from this source, which is in the public domain .
^ Cite error: The named reference pmid35043499
was invoked but never defined (see the help page ).
^ Cite error: The named reference pmid35298826
was invoked but never defined (see the help page ).